RAPT
Income statement / Annual
Last year (2023), RAPT Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, RAPT Therapeutics, Inc.'s net income was -$116.80 M.
See RAPT Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00
|
$1.53 M
|
$3.81 M
|
$5.04 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$3.55 M |
$2.81 M |
$996,000.00 |
$0.00 |
$1.33 M |
$1.24 M |
$1.38 M |
| Gross Profit |
-$3.55 M |
-$1.28 M |
$2.82 M |
$5.04 M |
-$1.33 M |
-$1.24 M |
-$1.38 M |
| Gross Profit Ratio |
0 |
-0.84 |
0.74 |
1 |
0 |
0 |
0 |
| Research and Development
Expenses |
$101.00 M
|
$67.08 M
|
$56.99 M
|
$45.49 M
|
$34.91 M
|
$31.77 M
|
$25.62 M
|
| General & Administrative
Expenses |
$26.06 M
|
$20.24 M
|
$16.04 M
|
$12.77 M
|
$8.72 M
|
$5.18 M
|
$3.71 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$26.06 M
|
$20.24 M
|
$16.04 M
|
$12.77 M
|
$8.72 M
|
$5.18 M
|
$3.71 M
|
| Other Expenses |
$0.00 |
$1.96 M |
$5,000.00 |
$1.31 M |
$1.29 M |
$800,000.00 |
$216,000.00 |
| Operating Expenses |
$127.06 M |
$87.32 M |
$73.02 M |
$58.26 M |
$43.63 M |
$36.95 M |
$29.33 M |
| Cost And Expenses |
$127.06 M |
$87.32 M |
$73.02 M |
$58.26 M |
$43.63 M |
$36.95 M |
$29.33 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.22 M
|
$2.81 M
|
$996,000.00
|
$1.12 M
|
$1.33 M
|
$1.24 M
|
$1.38 M
|
| EBITDA |
-$125.85 M
|
-$84.75 M
|
-$68.21 M
|
-$52.09 M
|
-$42.30 M
|
-$35.71 M
|
-$27.95 M
|
| EBITDA Ratio |
0 |
-56.19 |
-18.15 |
-10.55 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
-56.19
|
-18.15
|
-10.55
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$10.26 M
|
$1.96 M
|
$5,000.00
|
$1.31 M
|
$1.29 M
|
$800,000.00
|
$216,000.00
|
| Income Before Tax |
-$116.80 M |
-$83.84 M |
-$69.20 M |
-$51.90 M |
-$42.34 M |
-$36.15 M |
-$29.12 M |
| Income Before Tax Ratio
|
0
|
-54.9
|
-18.15
|
-10.29
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$1.96 M |
-$996,000.00 |
$990,000.00 |
$660,000.00 |
$800,000.00 |
$0.00 |
| Net Income |
-$116.80 M |
-$81.88 M |
-$68.21 M |
-$52.89 M |
-$43.00 M |
-$36.15 M |
-$29.12 M |
| Net Income Ratio |
0 |
-53.62 |
-17.89 |
-10.49 |
0 |
0 |
0 |
| EPS |
-3.05 |
-2.52 |
-2.49 |
-2.19 |
-1.97 |
-2.09 |
-2.01 |
| EPS Diluted |
-3.05 |
-2.52 |
-2.49 |
-2.19 |
-1.97 |
-2.09 |
-2.01 |
| Weighted Average Shares
Out |
$38.34 M
|
$32.54 M
|
$27.39 M
|
$24.13 M
|
$21.83 M
|
$17.33 M
|
$14.46 M
|
| Weighted Average Shares
Out Diluted |
$38.34 M
|
$32.54 M
|
$27.39 M
|
$24.13 M
|
$21.83 M
|
$17.33 M
|
$14.46 M
|
| Link |
|
|
|
|
|
|
|
